When the COVID-19 vaccine first became available, people eagerly signed up for coveted slots to boost their antibodies against the virus that shut down much of the world. But not everyone who rolled up their sleeve received equal protection from illness.
A significant proportion of the population has weakened immune systems, including cancer patients, those with autoimmune disease, and organ transplant recipients. The immune systems of these individuals are unable to ward off disease as effectively, and their responses to vaccines are not as robust. Now, Yale researchers have received a $12 million award from the NIH as part of the Human Immune Project Consortium (HIPC) to study vaccine responses in vulnerable groups, including patients with multiple sclerosis (MS) undergoing B cell depletion therapy, older adults including particularly vulnerable older residents of long-term care facilities, and individuals with sickle cell disease who have substantial and potentially disabling morbidity and early mortality for whom fundamental challenges to improve clinical outcomes remain… Continue reading.
WASHINGTON, D.C.—The American Institute for Medical and Biological Engineering (AIMBE) has announced the induction of Rong Fan, Ph.D., Associate Professor, Department of Biomedical Engineering, Yale University, to its College of Fellows.
Election to the AIMBE College of Fellows is among the highest professional distinctions accorded to a medical and biological engineer. The College of Fellows is comprised of the top two percent of medical and biological engineers. College membership honors those who have made outstanding contributions to “engineering and medicine research, practice, or education” and to “the pioneering of new and developing fields of technology, making major advancements in traditional fields of medical and biological engineering, or developing/implementing innovative approaches to bioengineering education.”
Dr. Fan was nominated, reviewed, and elected by peers and members of the College of Fellows for “outstanding contribution to the development and commercialization of single-cell high-plex cytokine profiling technologies and the impact on cancer immunotherapy.”